Search results
Results From The WOW.Com Content Network
NCI supports clinical trials studying new and more effective ways to detect and treat cancer. Find clinical trials for triple-negative breast cancer.
Our results build on findings from earlier trials involving patients with metastatic triple-negative breast cancer that showed greater single-agent activity with pembrolizumab and other...
A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
The purpose of this study is to evaluate the safety and effectiveness of combined treatment with niraparib and pembrolizumab (MK-3475) in patients who have triple-negative breast cancer that is advanced or has spread, or ovarian cancer that has returned after previous treatment.
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the...
Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the...
Adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer than if they received chemotherapy alone, new results from a clinical trial show.
Improved understanding of the interplay between triple-negative breast cancer (TNBC) tumour cells and their microenvironment supports the adoption of a new comprehensive view of this cancer...
PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1,2, who were germline BRCA1 and BRCA2 wild type...
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and...